BlackRock Fund Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BlackRock Fund Advisors’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$9.22M	Buy	1,195,897 +123,726	+12%	+$1.14M	﹤0.01%	2617
2016 Q3	$12.3M	Buy	1,072,171 +232,783	+28%	+$2.71M	﹤0.01%	2342
2016 Q2	$10.3M	Buy	839,388 +15,990	+2%	+$194K	﹤0.01%	2394
2016 Q1	$8.32M	Buy	823,398 +19,418	+2%	+$228K	﹤0.01%	2461
2015 Q4	$18.1M	Sell	803,980 -71,048	-8%	-$1.46M	﹤0.01%	2112
2015 Q3	$14.5M	Buy	875,028 +47,619	+6%	+$955K	﹤0.01%	2189
2015 Q2	$18.6M	Buy	827,409 +100,028	+14%	+$2.47M	﹤0.01%	2152
2015 Q1	$18.8M	Buy	727,381 +19,790	+3%	+$502K	﹤0.01%	2111
2014 Q4	$15.4M	Buy	707,591 +41,745	+6%	+$855K	﹤0.01%	2209
2014 Q3	$12.6M	Buy	665,846 +4,889	+0.7%	+$98.3K	﹤0.01%	2220
2014 Q2	$15.4M	Buy	660,957 +169,818	+35%	+$4.19M	﹤0.01%	2165
2014 Q1	$16.5M	Buy	491,139 +41,923	+9%	+$1.41M	﹤0.01%	2102
2013 Q4	$13.3M	Buy	449,216 +318,048	+242%	+$5.83M	﹤0.01%	2214
2013 Q3	$2.01M	Buy	+131,168	New	+$2.43M	﹤0.01%	3123

Other funds holding OMED

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's OMED Position: Q4 2016 in Review

BlackRock Fund Advisors increased its OncoMed Pharmaceuticals, Inc. (OMED) stake by 12% in Q4 2016, buying an estimated $1.14M and bringing the position to 1,195,897 shares worth $9.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

BlackRock Fund Advisors first reported a position in OMED in Q3 2013 and has held it in 14 quarters since. The position peaked at $18.8M in Q1 2015. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

BlackRock Fund Advisors held 1,195,897 shares of OncoMed Pharmaceuticals, Inc. worth $9.22M as of Q4 2016.
BlackRock Fund Advisors bought 123,726 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.14M.
OncoMed Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2617 holding.
BlackRock Fund Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and has held it in 14 quarters since.
BlackRock Fund Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $18.8M in Q1 2015.
86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.